For some medical conditions there are hundreds of bacteria shifts reported, for others only a few. The Percentage is based on the least number. If there are matches 8 matches for a condition that has 10 known bacteria shifts, against a condition that has 50 bacteria shifts. It will be 8/10 or 80% and not 8/50= 16%. The count of possible bacteria is shown for reference.
Limited to conditions with 5 or more bacteria
| Name | Overlap Percent | Prevalance in Population | Matches | Bacteria in From | Bacteria in To |
|---|---|---|---|---|---|
| Allergies | 24 % | 30% | 12 | 50 | 62 |
| Alzheimer's disease | 24 % | 10% | 12 | 50 | 62 |
| Autism | 32.3 % | 2% | 20 | 110 | 62 |
| Rosacea | 22.7 % | 5.46% | 5 | 22 | 62 |
| Ulcerative colitis | 40.3 % | 0.1% | 25 | 108 | 62 |
| Schizophrenia | 29 % | 0.75% | 18 | 93 | 62 |
| Ankylosing spondylitis | 43.5 % | 7% | 27 | 520 | 62 |
| Mood Disorders | 50 % | 29.7% | 3 | 6 | 62 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 38.7 % | 0.86% | 24 | 134 | 62 |
| Psoriasis | 21.7 % | 3% | 10 | 46 | 62 |
| Multiple Sclerosis | 32.3 % | 0.5% | 20 | 100 | 62 |
| Obesity | 30.6 % | 42.4% | 19 | 104 | 62 |
| Osteoporosis | 18.2 % | 9.4% | 4 | 22 | 62 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 18.6 % | 0.005% | 8 | 43 | 62 |
| neuropsychiatric disorders (PANDAS, PANS) | 46.7 % | 0.1% | 7 | 15 | 62 |
| ME/CFS without IBS | 15.4 % | 0.4% | 4 | 26 | 62 |
| Obesity | 10.9 % | 42.4% | 6 | 55 | 62 |
| Metabolic Syndrome | 42.9 % | 21% | 3 | 7 | 62 |
| ME/CFS with IBS | 31.6 % | 2.8% | 6 | 19 | 62 |
| Liver Cirrhosis | 53.2 % | 0.27% | 33 | 678 | 62 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 21 % | 25% | 13 | 76 | 62 |
| Parkinson's Disease | 25.8 % | 1% | 16 | 90 | 62 |
| Chronic Kidney Disease | 25.7 % | 15% | 9 | 35 | 62 |
| Systemic Lupus Erythematosus | 22.6 % | 0.15% | 14 | 66 | 62 |
| Depression | 27.4 % | 8% | 17 | 81 | 62 |
| IgA nephropathy (IgAN) | 31 % | 0.001% | 9 | 29 | 62 |
| Insomnia | 60 % | 30% | 6 | 10 | 62 |
| Hyperlipidemia (High Blood Fats) | 16 % | 33% | 4 | 25 | 62 |
| hypercholesterolemia (High Cholesterol) | 22.2 % | 12% | 2 | 9 | 62 |
| hypertension (High Blood Pressure | 50 % | 47% | 3 | 6 | 62 |
| Allergic Rhinitis (Hay Fever) | 11.1 % | 7.8% | 4 | 36 | 62 |
| Chronic Urticaria (Hives) | 30.4 % | 5% | 7 | 23 | 62 |
| gallstone disease (gsd) | 40 % | 5% | 6 | 15 | 62 |
| Graves' disease | 12.5 % | 0.5% | 1 | 8 | 62 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 12.5 % | 27.8% | 3 | 24 | 62 |
| Fibromyalgia | 21.6 % | 1.12% | 8 | 37 | 62 |
| Functional constipation / chronic idiopathic constipation | 26.8 % | 14% | 11 | 41 | 62 |
| Gout | 14.3 % | 6.8% | 3 | 21 | 62 |
| Epilepsy | 48 % | 0.84% | 12 | 25 | 62 |
| Cerebral Palsy | 41.2 % | 0.2% | 7 | 17 | 62 |
| Inflammatory Bowel Disease | 29 % | 1.3% | 18 | 66 | 62 |
| Type 1 Diabetes | 23.1 % | 0.19% | 12 | 52 | 62 |
| cystic fibrosis | 28.6 % | 0.03% | 2 | 7 | 62 |
| Carcinoma | 15.7 % | 1% | 8 | 51 | 62 |
| COVID-19 | 16.7 % | 50% | 6 | 36 | 62 |
| Colorectal Cancer | 30.6 % | 4.3% | 19 | 296 | 62 |
| Celiac Disease | 21 % | 1.4% | 13 | 67 | 62 |
| Chronic Fatigue Syndrome | 20 % | 3% | 11 | 55 | 62 |
| Coronary artery disease | 18.8 % | 6.7% | 3 | 16 | 62 |
| Crohn's Disease | 41.9 % | 0.3% | 26 | 141 | 62 |
| Barrett esophagus cancer | 12.5 % | 7% | 2 | 16 | 62 |
| Bipolar Disorder | 33.3 % | 3% | 11 | 33 | 62 |
| Asthma | 29.6 % | 8% | 8 | 27 | 62 |
| Atherosclerosis | 43.5 % | 50% | 27 | 524 | 62 |
| Acne | 42.1 % | 47% | 8 | 19 | 62 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 43.8 % | 52% | 7 | 16 | 62 |
| Generalized anxiety disorder | 21.4 % | 2.7% | 3 | 14 | 62 |
| Brain Trauma | 45.5 % | 0.367% | 10 | 22 | 62 |
| Sjögren syndrome | 24.4 % | 1.2% | 10 | 41 | 62 |
| Type 2 Diabetes | 50 % | 10.8% | 31 | 267 | 62 |
| Stress / posttraumatic stress disorder | 23.2 % | 5.2% | 13 | 56 | 62 |
| ADHD | 23.4 % | 9.4% | 11 | 47 | 62 |
| Hashimoto's thyroiditis | 21.4 % | 0.35% | 3 | 14 | 62 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.